The Systemic Hemodynamic Effects of Medetomidine, Medetomidine/Atropine Combination, and Atipamezole Reversal in Dogs
World Small Animal Veterinary Association World Congress Proceedings, 2007
Lyon Lee1; John Lee2; William Spillman2; K. Meisner2; Changbaig Hyun3; M. Hutinen4
1Prof, Western University, CA, USA; 2Virginia Tech; 3Kangwon University; 4Orion Pharma

Six young healthy mixed breed dogs of both sexes were used for this study. Following parameters were measured; arterial, central venous, and pulmonary arterial blood pressures; heart rates(HR); and cardiac output(CO). Immediately after baseline(BL) measurements(time 0), each dog received an IM injection of either a combination of medetomidine at 10mcg/kg and atropine at 0.04mg/kg(group MAA), or medetomidine at 10mcg/kg(group MA). Atipamezole at 50mcg/kg was administered IM one hour later(time 60; T60) to each dog. For comparison, the cardiopulmonary measurements were taken at 5 minute intervals for the first 20 minutes following each drug administration, then at 10 minute intervals for further 40 minutes, totaling to 120 minutes of entire measurement time.

HR decreased markedly in both groups at T5, but thereafter, in group MAA, markedly increased and then returned to BL by T60, whilst in group MA remained decreased until T60. Atipamezole increased HR in both groups. Mean arterial blood pressure(MABP) increased from 93mmHg(BL) to 133 within 5 minutes, peaked to 168mmHg at T20 and then gradually decreased to 121mmHg at T60, whilst in group MA, increased from 97mmHg(BL) to 118mmHg within five minutes, but gradually decreased to 104mmHg at T60. CO decreased markedly within five minutes in both groups, but, in group MAA, returned to BL within thirty minutes, whilst in group MA, CO remained decreased until time 60.

These results demonstrated while CO is better maintained, marked changes in MABP and HR warrant to avoid indiscriminate use of medetomidine with atropine in some patient population.

Speaker Information
(click the speaker's name to view other papers and abstracts submitted by this speaker)

Lyon Lee
Western University
California, USA


MAIN : Abstracts - Oral : Medetomidine & Atipamezole Reversal
Powered By VIN

Friendly Reminder to Our Colleagues: Use of VIN content is limited to personal reference by VIN members. No portion of any VIN content may be copied or distributed without the expressed written permission of VIN.

Clinicians are reminded that you are ultimately responsible for the care of your patients. Any content that concerns treatment of your cases should be deemed recommendations by colleagues for you to consider in your case management decisions. Dosages should be confirmed prior to dispensing medications unfamiliar to you. To better understand the origins and logic behind these policies, and to discuss them with your colleagues, click here.

Images posted by VIN community members and displayed via VIN should not be considered of diagnostic quality and the ultimate interpretation of the images lies with the attending clinician. Suggestions, discussions and interpretation related to posted images are only that -- suggestions and recommendations which may be based upon less than diagnostic quality information.

CONTACT US

777 W. Covell Blvd., Davis, CA 95616

vingram@vin.com

PHONE

  • Toll Free: 800-700-4636
  • From UK: 01-45-222-6154
  • From anywhere: (1)-530-756-4881
  • From Australia: 02-6145-2357
SAID=27